Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Daphne W. Dumoulin"'
Autor:
Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105074- (2024)
Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, so
Externí odkaz:
https://doaj.org/article/a26effef666d4b159c43d8ae59e8c674
Autor:
Daphne W. Dumoulin, Hester A. Gietema, Marthe S. Paats, Lizza E. L. Hendriks, Robin Cornelissen
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Immune checkpoint inhibitors (ICI) have become the standard of care treatment for several tumor types. ICI-induced pneumonitis is a serious complication seen with treatment with these agents. Cancer has been reported to be one of the risk factors for
Externí odkaz:
https://doaj.org/article/7ec4239e2ec54062bcab1737915b0dc8
Publikováno v:
Vaccines, Vol 9, Iss 5, p 525 (2021)
Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of
Externí odkaz:
https://doaj.org/article/78eab9f324ca458aafa1b8e6cca49bb5
Autor:
Nikki de Rouw, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus. J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine
Publikováno v:
Cancer Chemotherapy and Pharmacology, 91, 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Item does not contain fulltext PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89d8fdab2aea47b4e702192ee6d7831
https://hdl.handle.net/2066/290955
https://hdl.handle.net/2066/290955
Autor:
Ruben, Malmberg, Michiel, Zietse, Daphne W, Dumoulin, Jeroen J M A, Hendrikx, Joachim G J V, Aerts, Astrid A M, van der Veldt, Birgit C P, Koch, Stefan, Sleijfer, Roelof W F, van Leeuwen
Publikováno v:
The Lancet Oncology. 23:e552-e561
Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable responses to many patients with solid and haematological cancers. The high prices and increasing use of immune checkpoint inhibitors put considerable strain on heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f95a1398bb24def3d631fb9628db0c
https://doi.org/10.1016/s1470-2045(22)00554-x
https://doi.org/10.1016/s1470-2045(22)00554-x
Autor:
Jin, Yang, Ran, Zeng, Jianping, Zhou, Lifeng, Luo, Mengchen, Lyu, Fang, Liu, Xianwen, Sun, Ling, Zhou, Xiaofei, Wang, Zhiyao, Bao, Wei, Chen, Daphne W, Dumoulin, Beili, Gao, Yi, Xiang
Publikováno v:
Translational Lung Cancer Research, 11(6), 1038-1050. Society for Translational Medicine (STM)
Transl Lung Cancer Res
Transl Lung Cancer Res
Background: The rechallenge of immune checkpoint inhibitors (ICI) is now an optional strategy for patients who discontinued ICI due to immune-related adverse events (irAEs) or disease progression. However, little data is available for the prognosis a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056df96321127564f83b6b64c80d0eec
https://doi.org/10.21037/tlcr-22-360
https://doi.org/10.21037/tlcr-22-360
Autor:
Daphne W. Dumoulin, Paolo Bironzo, Francesco Passiglia, Giorgio V. Scagliotti, Joachim G.J.V. Aerts
Publikováno v:
European Respiratory Review, 32(167):220174. European Respiratory Society
Despite the progress in outcomes seen with immunotherapy in various malignancies, including nonsmall cell lung cancer, the benefits are less in small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. New effective treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee25fc76ba020c91cefb0ac72775c21e
https://pure.eur.nl/en/publications/a2b2f2b1-3d6e-4b3f-be60-e554ddacabfb
https://pure.eur.nl/en/publications/a2b2f2b1-3d6e-4b3f-be60-e554ddacabfb
Autor:
Simon P. de Leeuw, Melinda A. Pruis, Barend J. Sikkema, Mostafa Mohseni, G. D. Marijn Veerman, Marthe S. Paats, Daphne W. Dumoulin, Egbert F. Smit, Annemie M.W. J. Schols, Ron H.J. Mathijssen, Elisabeth F.C. van Rossum, Anne-Marie C. Dingemans
Publikováno v:
Journal of Thoracic Oncology. International Association for the Study of Lung Cancer
Introduction: Alectinib is a standard-of-care treatment for metastatic ALK+ NSCLC. Weight gain is an unexplored side effect reported in approximately 10%. To prevent or intervene alectinib-induced weight gain, more insight in its extent and etiology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62f56d54c35d15d0f74e0c396878e3f
https://doi.org/10.1016/j.jtho.2023.03.020
https://doi.org/10.1016/j.jtho.2023.03.020
Autor:
Rob ter Heine, Michel M. van den Heuvel, Berber Piet, Maarten J. Deenen, Anthonie J. van der Wekken, Lizza E. L. Hendriks, Sander Croes, Robin M. J. M. van Geel, Frank G. A. Jansman, Rogier C. Boshuizen, Eric J. F. Franssen, Arthur A. J. Smit, Daphne W. Dumoulin, Thijs H. Oude Munnink, Egbert F. Smit, Hieronymus J. Derijks, Cor H. van der Leest, Jeroen J. M. A. Hendrikx, Dirk J. A. R. Moes, Nikki de Rouw
Publikováno v:
Targeted Oncology, 18, 3, pp. 441-450
Targeted Oncology, 18(3), 441-450. Springer Paris
Targeted Oncology, 18, 441-450
Targeted Oncology, 18(3), 441-450. Springer Paris
Targeted Oncology, 18, 441-450
Contains fulltext : 292912.pdf (Publisher’s version ) (Open Access) BACKGROUND: Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide. OBJECTIV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b4dad43b54aa2ad8708876b6bbe71a
https://repository.ubn.ru.nl/handle/2066/292912
https://repository.ubn.ru.nl/handle/2066/292912
Autor:
Daphne W. Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Slooff, Nura Tebayna, Joanne M. Mankor, Sara J. Baart, Rudi Hendriks, Anne-Marie C. Dingemans, Marcella Willemsen, Joachim G.J.V. Aerts
Publikováno v:
European Journal of Cancer, 172, 357-366. Elsevier Ltd.
Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d806d365d895d4fde983300eefbfe7b1
https://pure.eur.nl/en/publications/c7ab20d9-63c7-41f2-95e2-02a4cf6bc3f1
https://pure.eur.nl/en/publications/c7ab20d9-63c7-41f2-95e2-02a4cf6bc3f1